11 Held the 2^nd User Meeting; (Oncosoft & VisionRT Joint User Meeting)
10 Business arrangements with Amazon Web Services (AWS)
09 Investment of KRW 11B (Series B)
09 OncoStudio distribution agreement with Anzai Medical in Japan
08 Validation of OncoStudio indication expansion with AI model for renal function measurement
08 Certified as Venture Enterprise
05 EN ISO 13485:2016 certified
03 Signed research contract with University of Chicago

12 Signed contract with Gachon University Gil Medical Center
11 Signed MoU with Terapet SA
11 Signed MoU with Yonsei Cancer Hospital Heavy Ion Therapy Center
10 Held the 1^st User Meeting ‘OncoBUS’
09 Signed MoU with Yonsei Digital Health Center
08 Signed contract with Japan M3 AI
08 Established Oncosoft USA Inc.
05 Signed MoU with Weknew
01 Signed MoU with Elketa

09 Investment of KRW 3.5B (Series A)
03 Commercialized OncoStudio (AI-based auto segmentation SW)
02 Acquired KFDA class II medical device certification for AI-based  auto-segmentation solution

11 Acquired Good Manufacturing Practice (GMP) certification for medical  device manufacturing and quality management
07 Investment of KRW 500M (Series Pre-A)
03 Established Corporate R&D Center

10 Investment of KRW 150M (Seed)

10 Ranked3^rd in AAPM’s ‘RT-MAC Challenge’
09 Established OncoSoft Inc.